This clinical trial tests gut-immune axis modulation in Parkinson's disease patients using a combination of prebiotic/probiotic/Vitamin D therapy. The study is based on growing evidence that the gut-brain axis plays a critical role in neurodegeneration and that alpha-synuclein pathology may originate in the enteric nervous system before spreading to the brain[1][2].
The gut-brain axis in Parkinson's disease involves complex bidirectional communication between the intestinal microbiome, the immune system, and the central nervous system. This connection has become increasingly recognized as a key factor in PD pathogenesis[3][4].
Several lines of evidence support the hypothesis that Parkinson's disease may originate in the gut:
The gut microbiome communicates with the brain through multiple pathways:
Chronic neuroinflammation is a hallmark of Parkinson's disease, characterized by activated microglia and elevated pro-inflammatory cytokines[13][14]:
The gut microbiome influences systemic inflammation through microbial metabolite production and immune cell modulation[15][16].
Vitamin D has multiple potential neuroprotective effects:
Vitamin D deficiency has been associated with increased PD risk and severity[17][18].
Phase: Phase 2, randomized, double-blind, placebo-controlled
Duration: 30 months (including 6-month follow-up after treatment period)
Target Enrollment: 120 Parkinson's disease patients
Power Calculation: 80% power to detect 4-point difference in MDS-UPDRS Part III at α=0.05
Stratified randomization by:
| Component | Dose | Timing |
|---|---|---|
| Prebiotic fiber (inulin-type) | 10g/day | Once daily with breakfast |
| Probiotic (Bifidobacterium + Lactobacillus) | 10^10 CFU/day | Once daily |
| Vitamin D3 | 4000 IU/day | Once daily |
Matching placebo for each component:
The intervention targets multiple pathways in the gut-brain axis:
Prebiotics (inulin-type fructans) and probiotics work synergistically to:
SCFAs, particularly butyrate, have anti-inflammatory properties and can cross the blood-brain barrier to modulate microglia[19][20].
Certain probiotic strains can modulate neuroinflammation by:
Vitamin D exerts neuroprotective effects through:
The combination approach targets multiple mechanisms simultaneously, potentially producing synergistic effects.
Mixed-effects model with repeated measures (MMRM):
| Category | Cost (USD) |
|---|---|
| Personnel (PI, coordinators, nurses) | $400,000 |
| Study drug (active and placebo) | $150,000 |
| Biomarker assays | $200,000 |
| Microbiome sequencing | $180,000 |
| MRI imaging (subset) | $120,000 |
| Clinical laboratory | $80,000 |
| Administrative costs | $120,000 |
| Contingency (15%) | $187,000 |
| Total | $1,437,000 |
| Month | Milestone |
|---|---|
| 0-3 | IRB approval, regulatory submissions, site setup |
| 3-6 | Patient recruitment initiation |
| 6-18 | Active patient recruitment |
| 18-24 | Treatment period for last-enrolled patient |
| 24-27 | Follow-up assessments |
| 27-30 | Data analysis, manuscript preparation |
| 30+ | Publication, regulatory reporting |
Braak et al. Staging of brain pathology related to sporadic Parkinson's disease (2003). 2003. ↩︎
Braak et al. 'Idiopathic Parkinson''s disease: possible routes by which vulnerable neuronal types may be initiated (2003)'. 2003. ↩︎
Sampson et al. Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease (2016). 2016. ↩︎
Poewe et al. Parkinson's disease (2022). 2022. ↩︎
Savica et al. 'Medical records and longitudinal studies: Do they tell the same story about the emergence of Parkinson''s disease? (2010)'. 2010. ↩︎
Postuma et al. Identifying prodromal Parkinson's disease (2015). 2015. ↩︎
Braak et al. Staging of brain pathology related to sporadic Parkinson's disease (2003). 2003. ↩︎
Shannon et al. Intestinal dysmotility contributes to alpha-synuclein pathology (2013). 2013. ↩︎
Gardet et al. LRRK2 is expressed in B cells (2010). 2010. ↩︎
Wandinger et al. LRRK2 and immune cells (2011). 2011. ↩︎
Keshavarzian et al. Colonic inflammation in Parkinson's disease (2015). 2015. ↩︎
Hill-Burns et al. Parkinson's disease and Parkinson's disease medications have distinct signatures in the microbiome (2017). 2017. ↩︎
Hirsch et al. Neuroinflammation in Parkinson's disease (2012). 2012. ↩︎
Tansey et al. Neuroinflammatory mechanisms in Parkinson's disease (2022). 2022. ↩︎
Erny et al. Host microbiota constantly control maturation and function of microglia (2015). 2015. ↩︎
Burokas et al. Targeting the microbiota-gut-brain axis (2017). 2017. ↩︎
Evatt et al. Prevalence of vitamin D insufficiency (2008). 2008. ↩︎
Fullard et al. Vitamin D and the risk of Parkinson's disease (2010). 2010. ↩︎
Bologna et al. Short chain fatty acids and neuroinflammation (2021). 2021. ↩︎
Silva et al. Butyrate and neuroinflammation (2020). 2020. ↩︎